Check Congress

Bill · 119th Congress

H.R. 8205

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Sent to PresidentIntroduced Apr 6, 2026Topic: Health →
  1. 01 Introduced
  2. 02 Committee
  3. 03 Passed House
  4. 04 Passed Senate
  5. 05 To President
  6. 06 Law

Latest action · Oct 26, 2026
Presented to President.

Read the bill text · Enrolled Bill ↗PDF ↗Congress.gov ↗
SummaryVotes 0Timeline 22Cosponsors 103Details

What this bill does

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The bill reauthorizes

  • grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
  • grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
  • a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. 

Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.

Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Congressional Research Service · Reported to House · Jul 9, 2026

How Congress voted

No recorded votes yet. Many bills pass by voice vote or unanimous consent, where no one's individual vote is written down.

Timeline

  1. Oct 26, 2026Presented to President.
  2. Oct 14, 2026Message on Senate action sent to the House.
  3. Sep 28, 2026Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
  4. Sep 28, 2026Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
  5. Jul 23, 2026Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
  6. Jul 22, 2026Motion to reconsider laid on the table Agreed to without objection.
  7. Jul 22, 2026On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  8. Jul 22, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  9. Jul 22, 2026Considered as unfinished business. (consideration: CR H5159)
  10. Jul 20, 2026At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
  11. Jul 20, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
  12. Jul 20, 2026Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
  13. Jul 20, 2026Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
  14. Jul 9, 2026Placed on the Union Calendar, Calendar No. 637.
  15. Jul 9, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
  16. May 21, 2026Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
  17. May 21, 2026Committee Consideration and Mark-up Session Held
  18. May 13, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
  19. May 13, 2026Subcommittee Consideration and Mark-up Session Held
  20. Apr 6, 2026Referred to the Subcommittee on Health.
  21. Apr 6, 2026Referred to the House Committee on Energy and Commerce.
  22. Apr 6, 2026Introduced in House

Cosponsors

103 members

Show all 103

Details

Related bills

S. 4472On Congress.gov ↗Related

Cost estimates · Congressional Budget Office

None published

Subject tags · 11

Department of Health and Human ServicesDrug therapyFood and Drug Administration (FDA)Government information and archivesHealth programs administration and fundingInternet, web applications, social mediaMedical researchNational Institutes of Health (NIH)Neurological disordersPublic-private cooperationResearch administration and funding